Vaccination of transgenic P301S mice, a mouse model for tauopathies, with the combination of two vectors, a DNA-Tau as a priming component (DNA-au4R2N or DNA-Tau3RC) and MVA-au as a booster (MVA-Tau4R2N or MVA-Tau3RC) was not able to decrease significantly the levels of hyperphosphorylated tau, a clinical sign of AD, nor have a significant impact on the motor capacity and survival rate. This evidence concerns the gene MAPT and tauopathy.